Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

Impact of Long-Term Treatment with Belantamab Mafodotin on Safety and Efficacy Outcomes in Patients with Relapsed/Refractory Multiple Myeloma in DREAMM-3

Blood (2023) 142 (Supplement 1): 3357.

https://doi.org/10.1182/blood-2023-178009

Published: 2023

Journal Articles

Concurrent Testing of Spatially Separated Tissue Samples and Circulating Tumor DNA Reveals Substantial Intra-Patient Genetic Heterogeneity in Relapsed/Refractory Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 171.

https://doi.org/10.1182/blood-2023-187554

Published: 2023

Journal Articles

Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

Blood (2023) 142 (Supplement 1): 2018.

https://doi.org/10.1182/blood-2023-177945

Published: 2023

Journal Articles

Caplacizumab Therapy in Immune Thrombotic Thrombocytopenic Purpura

Marienn Réti, György Sinkovits, Andrea Várkonyi, Ágnes Király, Zita Farkas, Luca Bogsch, Andreea-Adela Icleanu, Tamás Masszi, István Vályi-Nagy, Zoltán Prohászka, Péter Pál Reményi

Blood (2023) 142 (Supplement 1): 5436.

https://doi.org/10.1182/blood-2023-186633

Published: 2023

Journal Articles

Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen

Barbara Simon, Andrea Ceglédi, János Dolgos, Péter Farkas, Manila Gaddh, László Hankó, Robert Horváth, Ambrus Kaposi, Lászlóné Magyar, Tamás Masszi, Attila Szederjesi, Nikolett Wohner, Imre Bodó

Blood (2022) 140 (18): 1983–1992.

https://doi.org/10.1182/blood.2022016873

Published: 2022

Includes: Supplemental data

Journal Articles

OCEAN (OP-103): Melflufen Plus Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM) - Renal Impairment (RI) Analysis

Tadeusz Robak, Sosana Delimpasi, Ludek Pour, Tamas Masszi, Ivan Spicka, Wojciech Legiec, Pieter Sonneveld, Marcus Thuresson, Kajsa Larsson, Johan Harmenberg, Fredrik H. Schjesvold

Blood (2021) 138 (Supplement 1): 4777.

https://doi.org/10.1182/blood-2021-146550

Published: 2021

Journal Articles

Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR 4.5 : Results from ENESTfreedom

Jose Valentín García Gutiérrez, MD PhD, Jerald P. Radich, MD, Andreas Hochhaus, MD, Giuseppe Saglio, MD PhD, Tamas Masszi, MD PhD Prof., Andrzej Hellmann, MD PhD, Jesper Stentoft, MD PhD, María Teresa Gomez Casares, MD PhD, Eibhlin Conneally, MB, PhD MRCP, MRCPath, Philipp D le Coutre, MD, Norbert Gattermann, MD, Bruno Martino, MD, Susanne Saussele, MD, Francis J. Giles, MD FRCPI, FRCPath, Paola Aimone, MD, Sai Li, MD PhD, Ksenia Titorenko, MS, David M. Ross, MD MBBS, PhD FRACP, FRCPA

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-137388

Published: 2020

Journal Articles

Efficacy and Safety of Venetoclax Combinations in t(11;14) Multiple Myeloma: Real World Data Collected from 7 Hungarian Centers

Virág Réka Szita, MD, Gábor Mikala, MD PhD, János Fábián, MD, Péter Rajnics, MD PhD, László Rejtő, MD PhD, Tamás Szendrei, MD, Hussain Alizadeh, MD PhD DSc, Laszlo Varoczy, MD PhD, Árpád Illés, MD PhD, Tamas Masszi, MD PhD, Gergely Varga, MD PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-139870

Published: 2020

Journal Articles

Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial

Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Tamas Masszi, MD, Elena Mishchenko, MD, Mark W. Drummond, PhD FRCPath, Eric Jourdan, MD, Alessandro M. Vannucchi, MD, Mindaugas Jurgutis, Vincent Ribrag, MD, Alessandro Rambaldi, MD PhD, Liang Piu Koh, MBBS, MRCP, Shelonitda Rose, MD, Jun Zhang, PhD, Claire Harrison, DM, FRCP, FRCPath

Blood (2020) 136 (Supplement 1): 10–12.

https://doi.org/10.1182/blood-2020-137279

Published: 2020

Journal Articles

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

Craig H. Moskowitz, Jan Walewski, Auayporn Nademanee, Tamas Masszi, Edward Agura, Jerzy Holowiecki, Muneer H. Abidi, Andy I. Chen, Patrick Stiff, Simonetta Viviani, Veronika Bachanova, Anna Sureda, Teresa McClendon, Connie Lee, Julie Lisano, John Sweetenham

Blood (2018) 132 (25): 2639–2642.

https://doi.org/10.1182/blood-2018-07-861641

Published: 2018

Journal Articles

Real World Data on the Efficacy and Safety of Daratumumab in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Hematology Centers

Blood (2018) 132 (Supplement 1): 3257.

https://doi.org/10.1182/blood-2018-99-115039

Published: 2018

Journal Articles

Description of the First Cases with ADAMTS13 Mutations in Hungary

Marienn Réti, MD, György Sinkovits, MD, Orsolya Cseprekál, MD PhD, Dorottya Csuka, PhD, Ágnes Szilágyi, PhD, Zita Farkas, MD, Zsolt Klucsik, MD, Attila Szederjesi, MSC, László Wágner, MD Prof, György Reusz, MD Prof, Johanna A. Kremer Hovinga, MD Prof, János Rigó, MD Prof, Tamas Masszi, MD Prof., Zoltan Prohászka, MD Prof

Blood (2018) 132 (Supplement 1): 5003.

https://doi.org/10.1182/blood-2018-99-118327

Published: 2018

Journal Articles

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)

Blood (2018) 132 (Supplement 1): 1753.

https://doi.org/10.1182/blood-2018-99-115129

Published: 2018

Journal Articles

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

Blood (2017) 130 (24): 2610–2618.

https://doi.org/10.1182/blood-2017-06-791228

Published: 2017

Includes: Supplemental data

Journal Articles

Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)

Blood (2017) 130 (Supplement 1): 322.

https://doi.org/10.1182/blood.V130.Suppl_1.322.322

Published: 2017

Journal Articles

Real World Data on the Efficacy and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program

Gergely Varga, MD PhD, Zsolt Nagy, MD PhD, Szabolcs Kosztolányi, MD, Árpád Szomor, MD PhD, Tamás Schneider, MD PhD, Beáta Deák, MD PhD, Krisztina Wolf, MD, Márk Plander, MD PhD, Tamás Szendrei, MD, László Váróczy, MD PhD, Árpád Illés, MD PhD, Árpád Bátai, MD, Mónika Pető, MD, János Fábián, MD, Tamas Masszi, MD PhD, Gabor Mikala, MD PhD

Blood (2017) 130 (Supplement 1): 1865.

https://doi.org/10.1182/blood.V130.Suppl_1.1865.1865

Published: 2017

Journal Articles

Management and Outcome of Patients with Diffuse Large B-Cell Lymphoma Relapsed after Autologous Hemopoietic Stem Cell Transplantation (auto-HSCT): A Retrospective Analysis of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Blood (2017) 130 (Supplement 1): 2025.

https://doi.org/10.1182/blood.V130.Suppl_1.2025.2025

Published: 2017

Journal Articles

Final Results of a Prospective Randomized Multicenter Phase III Trial Comparing Treosulfan/Fludarabine to Reduced Intensity Conditioning with Busulfan/Fludarabine Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Elderly or Comorbid Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome

Dietrich W Beelen, MD PhD, Rudolf Trenschel, MD, Matthias Stelljes, MD, Tamás Masszi, MD Prof., Péter Reményi, Eva-Maria Maria Wagner-Drouet, MD, Peter Dreger, MD Prof., Wolfgang Bethge, MD Prof., Fabio Ciceri, MD, Friedrich Stoelzel, MD, Christian Junghanss, MD, Mauricette Michallet, MD Prof., Miroslaw Markiewicz, MD Prof.

Blood (2017) 130 (Supplement 1): 521.

https://doi.org/10.1182/blood.V130.Suppl_1.521.521

Published: 2017

Journal Articles

The Use of Anti-Thymocyte Globulin Is Associated with Increased Chance of Survival Free from Relapse and Graft-Versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation for Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia: An Analysis By the Acute Leukemia Working Party of the EBMT

Sebastian Giebel, Myriam Labopin, MD, Wlodzimierz Mendrek, Gerard Socie, MD PhD, Liisa Volin, MD PhD, Nathalie Fegueux, MD, Tamas Masszi, MD, Didier Blaise, MD PhD, Sridhar Chaganti, MD PhD MRCP, FRCPath, Jan J. Cornelissen, MD PhD, Jakob R Passweg, MD, Johan Maertens, MD PhD, Maija Itälä-Remes, Depei Wu, MDPhD, Mohamad Mohty, MD PhD, Arnon Nagler

Blood (2016) 128 (22): 666.

https://doi.org/10.1182/blood.V128.22.666.666

Published: 2016

Journal Articles

Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): High Efficacy of High Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC auto-SCT). A Study of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Saad Akhtar, MD, Silvia Montoto, MD, Ariane Boumendil, PhD, Luca Castagna, MD, Herve Finel, Tamas Masszi, MD, Pavel Jindra, MD PhD, Damir Nemet, MD PhD, Herrad Baurmann, MD, Yves Beguin, MD PhD, Felicetto Ferrara, Saveria Capria, MD, Ram Malladi, MD PhD, Jose M Moraleda, MD PhD, Gilles Salles, MD PhD, Adrian Bloor, Julia Meissner, MD, Anna Sureda, MD, Peter Dreger, MD

Blood (2016) 128 (22): 514.

https://doi.org/10.1182/blood.V128.22.514.514

Published: 2016

NARROW

Impact of Long-Term Treatment with Belantamab Mafodotin on Safety and Efficacy Outcomes in Patients with Relapsed/Refractory Multiple Myeloma in DREAMM-3

Concurrent Testing of Spatially Separated Tissue Samples and Circulating Tumor DNA Reveals Substantial Intra-Patient Genetic Heterogeneity in Relapsed/Refractory Follicular Lymphoma

Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

Caplacizumab Therapy in Immune Thrombotic Thrombocytopenic Purpura

Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen

OCEAN (OP-103): Melflufen Plus Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM) - Renal Impairment (RI) Analysis

Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR 4.5 : Results from ENESTfreedom

Efficacy and Safety of Venetoclax Combinations in t(11;14) Multiple Myeloma: Real World Data Collected from 7 Hungarian Centers

Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

Real World Data on the Efficacy and Safety of Daratumumab in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Hematology Centers

Description of the First Cases with ADAMTS13 Mutations in Hungary

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)

Real World Data on the Efficacy and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program

Management and Outcome of Patients with Diffuse Large B-Cell Lymphoma Relapsed after Autologous Hemopoietic Stem Cell Transplantation (auto-HSCT): A Retrospective Analysis of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): High Efficacy of High Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC auto-SCT). A Study of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only